

Price Inflation Impacts Healthcare Costs (Trend) in 2024

Leading 2024 Cost Drivers - Rising Cost of GLP-1s

New diabetes therapies have seen a significant increase, driven by GLP-1 used for both diabetes and obesity. While GLP-1 medications have shown significant glucose control as well as cardiovascular outcome benefits, a key factor in their increased utilization is likely due to the profound weight loss possible with these medications. The tremendous growth in this drug class is attributable to many factors, including updates to American Diabetes Association recommendations for GLP-1 agonists to reduce health complications, the off-label, weight-loss use stemming from social media buzz and exponential market investments in anti-obesity drugs.

